Ono Pharmaceutical Co., Ltd.

TSE:4528 Stock Report

Market Cap: JP¥1.0t

Ono Pharmaceutical Valuation

Is 4528 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4528 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4528 (¥2218) is trading below our estimate of fair value (¥4875.37)

Significantly Below Fair Value: 4528 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4528?

Other financial metrics that can be useful for relative valuation.

4528 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.7x
Enterprise Value/EBITDA4.8x
PEG Ratio-0.7x

Price to Earnings Ratio vs Peers

How does 4528's PE Ratio compare to its peers?

The above table shows the PE ratio for 4528 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average34.6x
4151 Kyowa Kirin
19.7x2.0%JP¥1.6t
4507 Shionogi
11.5x-0.7%JP¥1.9t
4581 Taisho Pharmaceutical Holdings
83.5x18.2%JP¥703.3b
4536 Santen Pharmaceutical
23.7x8.4%JP¥631.7b
4528 Ono Pharmaceutical
8.1x-11.2%JP¥1.0t

Price-To-Earnings vs Peers: 4528 is good value based on its Price-To-Earnings Ratio (8.1x) compared to the peer average (34.6x).


Price to Earnings Ratio vs Industry

How does 4528's PE Ratio compare vs other companies in the JP Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.6%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.6%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 4528 is good value based on its Price-To-Earnings Ratio (8.1x) compared to the JP Pharmaceuticals industry average (19.1x).


Price to Earnings Ratio vs Fair Ratio

What is 4528's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4528 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio8.1x
Fair PE Ratio17.4x

Price-To-Earnings vs Fair Ratio: 4528 is good value based on its Price-To-Earnings Ratio (8.1x) compared to the estimated Fair Price-To-Earnings Ratio (17.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4528 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥2,218.00
JP¥2,370.77
+6.9%
27.8%JP¥4,370.00JP¥1,800.00n/a13
Jul ’25JP¥2,221.00
JP¥2,505.83
+12.8%
26.8%JP¥4,370.00JP¥1,900.00n/a12
Jun ’25JP¥2,275.00
JP¥2,597.50
+14.2%
32.9%JP¥5,170.00JP¥1,900.00n/a12
May ’25JP¥2,324.00
JP¥2,714.17
+16.8%
29.3%JP¥5,170.00JP¥2,000.00n/a12
Apr ’25JP¥2,468.50
JP¥2,672.50
+8.3%
30.8%JP¥5,170.00JP¥1,800.00n/a12
Mar ’25JP¥2,487.50
JP¥2,689.17
+8.1%
30.7%JP¥5,170.00JP¥1,800.00n/a12
Feb ’25JP¥2,525.50
JP¥2,720.77
+7.7%
28.5%JP¥5,170.00JP¥2,000.00n/a13
Jan ’25JP¥2,516.00
JP¥2,747.69
+9.2%
27.6%JP¥5,170.00JP¥2,100.00n/a13
Dec ’24JP¥2,708.00
JP¥2,755.38
+1.7%
27.4%JP¥5,170.00JP¥2,100.00n/a13
Nov ’24JP¥2,561.00
JP¥2,733.08
+6.7%
24.5%JP¥4,780.00JP¥2,100.00n/a13
Oct ’24JP¥2,868.00
JP¥2,870.91
+0.1%
26.4%JP¥4,780.00JP¥2,100.00n/a11
Sep ’24JP¥2,768.50
JP¥2,844.62
+2.7%
24.7%JP¥4,780.00JP¥2,100.00n/a13
Aug ’24JP¥2,705.00
JP¥2,829.23
+4.6%
25.1%JP¥4,780.00JP¥2,100.00n/a13
Jul ’24JP¥2,606.00
JP¥2,881.67
+10.6%
24.7%JP¥4,780.00JP¥2,200.00JP¥2,221.0012
Jun ’24JP¥2,620.50
JP¥3,038.46
+15.9%
22.6%JP¥4,700.00JP¥2,200.00JP¥2,275.0013
May ’24JP¥2,753.00
JP¥3,184.62
+15.7%
19.9%JP¥4,700.00JP¥2,500.00JP¥2,324.0013
Apr ’24JP¥2,764.00
JP¥3,215.38
+16.3%
18.9%JP¥4,700.00JP¥2,500.00JP¥2,468.5013
Mar ’24JP¥2,782.50
JP¥3,276.92
+17.8%
18.3%JP¥4,700.00JP¥2,500.00JP¥2,487.5013
Feb ’24JP¥2,863.00
JP¥3,308.33
+15.6%
13.7%JP¥4,100.00JP¥2,700.00JP¥2,525.5012
Jan ’24JP¥3,083.00
JP¥3,810.00
+23.6%
15.0%JP¥4,530.00JP¥2,700.00JP¥2,516.0013
Dec ’23JP¥3,498.00
JP¥3,794.62
+8.5%
15.0%JP¥4,530.00JP¥2,700.00JP¥2,708.0013
Nov ’23JP¥3,369.00
JP¥3,779.23
+12.2%
15.1%JP¥4,530.00JP¥2,700.00JP¥2,561.0013
Oct ’23JP¥3,381.00
JP¥3,775.38
+11.7%
15.0%JP¥4,530.00JP¥2,700.00JP¥2,868.0013
Sep ’23JP¥3,368.00
JP¥3,752.31
+11.4%
15.2%JP¥4,530.00JP¥2,700.00JP¥2,768.5013
Aug ’23JP¥3,620.00
JP¥3,715.00
+2.6%
15.5%JP¥4,530.00JP¥2,700.00JP¥2,705.0012
Jul ’23JP¥3,452.00
JP¥3,579.23
+3.7%
14.8%JP¥4,530.00JP¥2,700.00JP¥2,606.0013

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.